Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target boosted by Chardan Capital from $88.00 to $91.00 in a research report released on Monday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Chardan Capital also issued estimates for Intellia Therapeutics’ FY2025 earnings at ($4.14) EPS.

NTLA has been the topic of several other reports. Barclays decreased their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Stifel Nicolaus dropped their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Finally, Robert W. Baird reduced their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $13.86 on Monday. The company’s 50 day simple moving average is $18.26 and its two-hundred day simple moving average is $21.85. Intellia Therapeutics has a 1 year low of $12.82 and a 1 year high of $34.87. The stock has a market capitalization of $1.41 billion, a PE ratio of -2.55 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.38) EPS. On average, research analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently made changes to their positions in the business. First Horizon Advisors Inc. raised its position in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares during the period. Elmwood Wealth Management Inc. grew its holdings in Intellia Therapeutics by 0.9% during the third quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock valued at $1,393,000 after purchasing an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares in the last quarter. Capstone Investment Advisors LLC raised its stake in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after buying an additional 831 shares during the period. Finally, Axxcess Wealth Management LLC lifted its position in shares of Intellia Therapeutics by 6.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock valued at $457,000 after buying an additional 1,010 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.